DMAC2L

Across TCGA pan-cancer cohorts, DMAC2L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DMAC2L data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DMAC2L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DMAC2L expression acts as an unfavorable survival marker, although some lineages such as COAD and CCRCC show a favorable association.

LUAD, COAD, and HNSC are the cancer types where DMAC2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.372	0.886	.002	30	view →
COAD	DFS	Tertile	All	1.000	0.900	.026	24	view →
HNSC	DFS	Quartile	All	0.647	0.855	.015	15	view →
UCEC	DFS	Median	II,III,IV	0.530	0.885	.015	8	view →
OV	DFS	Median	All	0.870	1.000	.046	4	view →
CCRCC	OS	Quartile	All	0.894	0.676	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DMAC2L–LUAD (DFS)

Open the LUAD breakdown →